Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS
|
March 16, 2023
Safety and Efficacy of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Veterans With Type 2 Diabetes
Lauren McCulley, Kathryn M Hurren
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
November 25, 2010
Probable interaction between warfarin and bee pollen
Kathryn M Hurren, Carrie L Lewis
Expert Opinion on Pharmacotherapy
|
December 7, 2020
Are thiazolidinediones a preferred drug treatment for type 2 diabetes?
Kathryn M Hurren, Marissa Waldman Dunham
The Annals of Pharmacotherapy
|
July 7, 2011
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis
Nicole R Pinelli, Kathryn M Hurren
Expert Opinion on Drug Metabolism & Toxicology
|
June 28, 2013
Evaluation of lorcaserin for the treatment of obesity
Helen D Berlie, Kathryn M Hurren
Expert Opinion on Drug Metabolism & Toxicology
|
June 22, 2017
Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity
Kathryn M Hurren, Marissa W Dunham
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
October 21, 2011
Lorcaserin: an investigational serotonin 2C agonist for weight loss
Kathryn M Hurren, Helen D Berlie
Expert Opinion on Pharmacotherapy
|
June 30, 2018
Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes
Kathryn M Hurren, Marissa W Dunham
Expert Opinion on Drug Metabolism & Toxicology
|
October 7, 2016
Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes
Kathryn M Hurren, Jessica L O'Neill
The Annals of Pharmacotherapy
|
April 19, 2012
Drug-drug interactions with glucagon-like peptide-1 receptor agonists
Kathryn M Hurren, Nicole R Pinelli
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS
|
March 16, 2023
Safety and Efficacy of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Veterans With Type 2 Diabetes
Lauren McCulley, Kathryn M Hurren
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
November 25, 2010
Probable interaction between warfarin and bee pollen
Kathryn M Hurren, Carrie L Lewis
Expert Opinion on Pharmacotherapy
|
December 7, 2020
Are thiazolidinediones a preferred drug treatment for type 2 diabetes?
Kathryn M Hurren, Marissa Waldman Dunham
The Annals of Pharmacotherapy
|
July 7, 2011
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis
Nicole R Pinelli, Kathryn M Hurren
Expert Opinion on Drug Metabolism & Toxicology
|
June 28, 2013
Evaluation of lorcaserin for the treatment of obesity
Helen D Berlie, Kathryn M Hurren
Expert Opinion on Drug Metabolism & Toxicology
|
June 22, 2017
Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity
Kathryn M Hurren, Marissa W Dunham
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
October 21, 2011
Lorcaserin: an investigational serotonin 2C agonist for weight loss
Kathryn M Hurren, Helen D Berlie
Expert Opinion on Pharmacotherapy
|
June 30, 2018
Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes
Kathryn M Hurren, Marissa W Dunham
Expert Opinion on Drug Metabolism & Toxicology
|
October 7, 2016
Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes
Kathryn M Hurren, Jessica L O'Neill
The Annals of Pharmacotherapy
|
April 19, 2012
Drug-drug interactions with glucagon-like peptide-1 receptor agonists
Kathryn M Hurren, Nicole R Pinelli
Page
of 2